Invested $200K in BioClé, a bacterial extracellular vesicle platform for bioactive delivery, through GFIF II Cohort 4.
BioClé develops an intelligent delivery platform based on bacterial extracellular vesicles (bEVs) to enhance the bioavailability and efficacy of bioactive compounds in the gut
BioClé develops an intelligent delivery platform based on bacterial extracellular vesicles (bEVs) to enhance the bioavailability and efficacy of bioactive compounds in the gut. The technology ensures that ingredients like butyrate reach intestinal cells intact, boosting their effectiveness and enabling next-generation formulations for gut health.